UQ COVID-19 Vaccine Candidate Description
University of Queensland developed a rapid response “molecular clamp” vaccine platform, a transformative technology patented by UniQuest, UQ’s technology transfer company that enables rapid vaccine design and production against outbreak viral pathogens.
CEPI expanded its partnership with UQ in January 2020, to use its rapid response molecular clamp vaccine platform to produce a vaccine candidate for COVID-19.
UQ is now aiming to take the vaccine candidate into a phase 1 clinical trial in July.
Enveloped viruses have proteins on their surface that drive fusion of the virus and host cell membranes, a key process in infection.
These proteins are also the major target of a protective immune response.
Although they are able to induce an immune response, they are inherently unstable and can change shape when expressed on their own. This means that the immune response induced does not efficiently recognize the protein on the virus surface and so does not provide protection from subsequent infection.
UQ has overcome this problem by using its proprietary “molecular clamp” technology that locks the unstable, prefusion version of the surface proteins in a form that allows the immune system to respond more effectively.
This is achieved using their proprietary “molecular clamp” technology that locks these proteins in their native virus surface form. This synthetic protein can then be purified and rapidly manufactured into a vaccine.
Most recently, early preclinical results of the UQ COVID-19 vaccine candidate showed that it produced high levels of antibodies that can neutralize the virus.
The UQ COVID-19 vaccine will be combined with Seqirus’ well-established adjuvant technology – MF59® to improve immune response, reduce the amount of antigen needed for each vaccine, and enable more doses to be manufactured more rapidly.
UQ COVID-19 Vaccine Candidate Indication
UQ COVID-19 vaccine candidate is to prevent COVID-19 disease caused by infection with SARS-CoV-2.
UQ COVID-19 Vaccine Candidate News
June 5, 2020 - CEPI and The University of Queensland (UQ) announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture, and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ.
April 29, 2020 - The University of Queensland’s COVID-19 vaccine candidate has shown the ability to raise high levels of antibodies that can neutralize the virus in early pre-clinical testing.
UQ COVID-19 Vaccine Candidate Clinical Trials
Pending phase 1 study.